Search Results

Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in Sjögren’s disease, the pharma reported at the American College of Rheumatology Convergence congress on Wednesday.

Genentech is letting go of 118 employees in South San Francisco. The news comes about two months after the biotech ended a partnership with Adaptive Biotechnologies.

Shingrix sales in the U.S. took a 15% dive in the third quarter. GSK is now the second Big Pharma to report declining vaccine sales, after Sanofi reported a similar decline last week.

Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a genetic thyroid disorder.

The Company looks to build on its recent momentum - receiving FDA approval to expand its pivotal clinical trial into the second and final stage

X-ray crystallography is a powerful tool for fragment-based drug discovery (FBDD), providing detailed insights into fragment binding and enabling structure-guided optimization. In this talk, Dr. May Sharpe will present the Fast Fragment and Compound Screening (FFCS) pipeline at the Swiss Light Source (PSI) and share the first results from a collaborative screening campaign with Chemspace, featuring the REAL Crystallographic Fragment Library — the first dataset acquired at the newly upgraded SLS2.0 PXIII beamline.